Alivus Life Sciences Limited (ALIVUS) is trading at ₹1,397.4. The price shown is the latest available from the exchange feed and updates through the trading session.

ALIVUS trades at a P/E of 26.4. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.

ALIVUS has a dividend yield of 0.37%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.

ALIVUS has traded between ₹819 and ₹1,493.8 over the past year. The Trading Data block shows where the current price sits inside that band.

Alivus Life Sciences Limited has a market capitalisation of ₹16,417 crore.

ALIVUS reports a return on equity of 17.9%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.

The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.

Promoters hold 74.87% of ALIVUS. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.

Index membership is listed in the Context block on this page, along with the weight ALIVUS carries in each. That weight is what determines how much passive money tracks the stock.

We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from ALIVUS’s own numbers. The judgement is yours.